A5008661392- Amyloidosis: Diagnosis, Treatment, Outcomes
- Opioid Use Disorder Treatment
- Peptidase Inhibition and Analysis
- Pain Management and Opioid Use
- Substance Abuse Treatment and Outcomes
- Comparative Literary Analysis and Criticism
- Poisoning and overdose treatments
- Galician and Iberian cultural studies
- HIV, Drug Use, Sexual Risk
- Eosinophilic Disorders and Syndromes
- Dermatological and Skeletal Disorders
- Medieval Iberian Studies
- Parathyroid Disorders and Treatments
Ionis Pharmaceuticals (United States)
2022-2024
Diagnosis of hereditary amyloid transthyretin (hATTR) amyloidosis with cardiomyopathy is frequently delayed, in large part because symptom overlap other cardiovascular diseases and limited provider knowledge this disease. The sponsored referred hATTR Compass Genetic Testing Program (Ionis, Carlsbad, CA; Ambry Genetics, Aliso Viejo, CA) provided no-cost genetic testing to adults a family history or clinical suspicion amyloidosis. This study aims characterize patients increase awareness for hATTR.
Introduction: Hereditary amyloid transthyretin (hATTR, or ATTRv [variant]) amyloidosis is a progressive and fatal disease caused by alterations in the ( TTR ) gene that result deposition of misfolded protein throughout body, leading to multisystem dysfunction. The p.V142I p.T80A pathogenic typically manifest with cardiac phenotype, early diagnosis crucial achieving optimal patient outcomes. hATTR Compass Program offers confidential genetic testing patients suspected having United States,...